Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06238258 · ClinicalTrials.gov registry record · NA
Dual Diagnosis Training Trial
A NA study of Training Group, sponsored by University of New Mexi.
- Recruiting
- Registry status
- NA
- Development phase
- 55
- Enrollment target
- 1
- Study location
NCT06238258: Recruiting NA study of Training Group, sponsored by University of New Mexi.
NCT06238258 is a NA study of Training Group that is actively recruiting participants, run by University of New Mexi. The registered enrollment target is 55 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06238258, a NA study of Training Group, is actively recruiting participants, sponsored by University of New Mexi.
- RECRUITING
- Registry status
- NA
- Development phase
- 55 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a clinical trial, with participants undergoing the 16 hour SPECTROM training, and completing 2 assessments before and after training (the Psychotropic Knowledge Questionnaire-Revised and the Management of Aggression and Violence Attitude Scale-Revised-ID).
Primary Outcome
Completion of assessments
Conditions Studied
Interventions
- BEHAVIORAL SPECTROM Training
Study Locations (1)
New Mexico
- UNM Health Science Center - Albuquerque
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2024-07-01 |
| Est. Completion | 2026-03-01 |
| Phase | NA |
What NCT06238258 shows while recruiting
NCT06238258 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 55 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower).
The record links to 1 condition, with Training Group appearing as the primary indexed condition, and to 1 intervention - of which SPECTROM Training is the first listed.
NCT06238258 reports a single indexed study location in New Mexico.
Frequently Asked Questions
What is clinical trial NCT06238258 about?
NCT06238258 is a clinical study titled "Dual Diagnosis Training Trial". This is a clinical trial, with participants undergoing the 16 hour SPECTROM training, and completing 2 assessments before and after training (the Psychotropic Knowledge Questionnaire-Revised and the Management of Aggression and Violence Attitude Scale-Revised-ID).
What is the current status of trial NCT06238258?
This trial is currently recruiting. It is a NA study. The enrollment target is 55 participants. The study started on 2024-07-01. Estimated completion is 2026-03-01.
What conditions does trial NCT06238258 study?
This clinical trial studies the following conditions: Training Group.
What interventions are being tested in trial NCT06238258?
The interventions under investigation include: SPECTROM Training (BEHAVIORAL).
Who is sponsoring clinical trial NCT06238258?
This trial is sponsored by University of New Mexi, which has 76 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06238258 being conducted?
This trial has 1 study location across New Mexico. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06238258's enrollment target sits among peer trials
55 1264th of 2000 higher than 733 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01638676 · 55 participants · Phase 1
A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients
- NCT01906385 · 55 participants · Phase 1
Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)
- NCT03007030 · 55 participants · Phase 2
Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery
- NCT03152058 · 55 participants · Phase 2
IMPACT Study: IMProve Pregnancy in APS With Certolizumab Therapy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI